Lakefront Biotherapeutics (LKFT) vs Sarepta Therapeutics (SRPT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Lakefront Biotherapeutics (LKFT) has outperformed Sarepta Therapeutics (SRPT) over the past year, losing 14.5% versus a loss of 22.1%. Over five years, LKFT leads with a -44.9% price change compared with -78.4% for SRPT. Lakefront Biotherapeutics is the larger company by market cap ($1.93 billion vs $1.92 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LKFT | SRPT |
|---|---|---|
| Share price | $29.51 | $18.21 |
| Market cap | $1.93B | $1.92B |
| 1-day change | -1.63% | +4.06% |
| YTD return | -9.76% | -15.38% |
| 1-year return | -14.46% | -22.11% |
| 5-year return | -44.86% | -78.37% |
| P/E ratio (TTM) | 2.81 | — |
| Forward P/E | — | 7.55 |
| EPS (TTM) | $10.52 | $-1.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $2.20B |
| Revenue growth (YoY) | — | +15.58% |
| Net income (latest FY) | — | $-713.41M |
| Gross margin | — | 98.84% |
| Operating margin | — | -31.83% |
| Net margin | — | -32.45% |
| 52-week high | $36.24 | $24.68 |
| 52-week low | $25.68 | $14.68 |
| Distance from 52-week high | -18.57% | -26.22% |
| Analyst consensus | hold | hold |
| Avg. price target upside | +2.27% | +19.33% |
| Average volume | 273.30K | 2.99M |
| Shares outstanding | 65.48M | 105.63M |
| Employees | 196 | 835 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Lakefront Biotherapeutics
LKFT stock →Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
Health Care · Biotechnology: Pharmaceutical Preparations · 196 employees
About Sarepta Therapeutics
SRPT stock →Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.
Health Care · Biotechnology: Pharmaceutical Preparations · 835 employees
LKFT vs SRPT FAQ
Which is bigger, Lakefront Biotherapeutics or Sarepta Therapeutics?
Lakefront Biotherapeutics (LKFT) is larger, with a market capitalization of $1.93B compared with $1.92B for Sarepta Therapeutics (SRPT).
Which stock has performed better over the past year, LKFT or SRPT?
LKFT returned -14.46% over the past 12 months, compared with -22.11% for SRPT (price return, excluding dividends). Past performance does not predict future results.
Are Lakefront Biotherapeutics and Sarepta Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.